Clinical Transplantation and the Immunology of Organ Rejection

  • John J. Fung
  • J. Andrew Bradley


Transplantation of tissue between areas of the same individual is termed autografting and is not subject to rejection. Tissues transplanted between genetically identical individuals (syngeneic grafting) is termed isografting. Allografts (also known as homografts) are tissues transplanted between genetically disparate individuals within the same species. Xenografts (also known as heterografts) are tissues transplanted between disparate species.


Ischemia Lymphoma Anemia Glucocorticoid Cyclosporin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ponticelli C, Tarantino A, Segoloni G, et al. A randomised study comparing three cyclosporinbased regimens in cadaveric renal transplantation. J Am Soc Nephrol 1997;8:638–45.PubMedGoogle Scholar
  2. 2.
    Thiel G, Bock A, Spondlin M, et al. Long-term benefits and risks of cyclosporin-A (Sandimmun): an analysis at 10 years. Transplant Proc 1994;26:2493–8.PubMedGoogle Scholar
  3. 3.
    Szczech L, Berlin J, Aradhye S, et al. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol 1997;8:1771–7.PubMedGoogle Scholar
  4. 4.
    Szczech L, Berlin J, Feldman HI, et al. The effect of anti-lymphocyte induction therapy on renal allograft survival. Ann Intern Med 1998;128:817–26.PubMedCrossRefGoogle Scholar
  5. 5.
    Katznelson S, Cecka J. Immunosuppressive regimens and their effects on renal allograft outcome. In: Cecka J, Terasaki P. Editors. Clinical Transplants Los Angeles, CA: UCLA Tissue Typing Laboratory, 1996;361–71.Google Scholar
  6. 6.
    Mathew TH and the Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, long-term, randomised multicentre study of mycophenolate mofetil in cadaveric renal transplantation. Results at three years. Transplantation 1998;65:1450–4.PubMedCrossRefGoogle Scholar
  7. 7.
    European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 1999;68:391–6.CrossRefGoogle Scholar
  8. 8.
    Humar A, Hassoun A, Kandaswamy R. Immunologic factors: the major risk for decreased renal allograft survival. Transplantation 1999;68:1842–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Vereerstraeten P, Abramowicz D, De Pauw L et al. Absence of a deleterious effect on long-term kidney graft survival of rejection episodes with complete functional recovery. Transplantation 1997;63:1739–43.PubMedCrossRefGoogle Scholar
  10. 10.
    Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988–1996. N Eng J Med 2000;342:605–12.CrossRefGoogle Scholar
  11. 11.
    Fricke L, Klutter H, Feddersen A, et al. Pre-operative application of glucocorticoids efficaciously reduces the primary immunological response in kidney transplantation. Clin Transplant 1996;10:432–6.PubMedGoogle Scholar
  12. 12.
    US Renal Transplant Mycophenolate Mofetil Study Group, Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995;60:225–32.PubMedCrossRefGoogle Scholar
  13. l3.
    Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomised clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996;61:1029–37.CrossRefGoogle Scholar
  14. 14.
    European Mycophenolate Mofetil Study Group. Placebo controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995;345:1321–5.CrossRefGoogle Scholar
  15. 15.
    Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000;69:2405–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Gore SM, Oldham JA. Randomised trials of high-and low-dose steroids in renal transplantation. Transplantation 1986;41:319.PubMedCrossRefGoogle Scholar
  17. 17.
    Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporin for immunosuppression after cadaveric renal transplantation. Transplantation 1997;63:977–83.PubMedCrossRefGoogle Scholar
  18. 18.
    Mayer AD, Dmitrewski J, Squifflet JP et al. Multicenter randomized trial comparing tacrolimus and cyclosporine in the prevention of renal allograft rejection. A report of the European tacrolimus multicenter renal study group. Transplantation;1997,64:436.PubMedCrossRefGoogle Scholar
  19. 19.
    Ojo AO, Wolfe RA, Held PJ, et al. Delayed graft function: risk factors and implications for renal graft survival. Transplantation 1997;63:968.PubMedCrossRefGoogle Scholar
  20. 20.
    Kasiske B, Johnson H, Goerdt P, et al. A randomised trial comparing cyclosporin induction with sequential therapy in renal transplant recipients. Am J Kidney Dis 1997;30:639–45.PubMedCrossRefGoogle Scholar
  21. 21.
    Hong JC, Kahan BD. Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporin treatment during the induction phase of immunosuppression. Transplantation 1999;68:701–4PubMedCrossRefGoogle Scholar
  22. 22.
    Land W. Mycophenolate mofetil-based immunosuppressive therapy: induction, maintenance and conversion protocols in renal transplantation. Transplant Proc 1999;31:27–32.CrossRefGoogle Scholar
  23. 23.
    Hornberger J, Best J, Geppert J, et al. Risks and costs of end stage renal disease after heart transplantation. Transplantation 1998;66:1763–70.PubMedCrossRefGoogle Scholar
  24. 24.
    Jain A, Reyes J, Kashyap R, et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow up of the first 1,000 patients. Ann Surg 1999;230:441–9.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Abramowicz D, Manas D, Lao M, et al. Preliminary results of a randomised controlled study investigating the withdrawal of Neoral in stable renal transplants receiving mycophenolate mofetil in addition to Neoral and steroids. Transplantation 1999;67(suppl):240.CrossRefGoogle Scholar
  26. 26.
    De Sevaux RG, Smak-Gregor PI, Hene RJ et al. Withdrawal of cycJosporine or prednisolone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine and prednisolone: a randomised study. Transplantation 1999;67(suppl):240.CrossRefGoogle Scholar
  27. 27.
    Groth CG, Backman L, Morales J-M, et al. Sirolimus (Rapamycin)-based therapy in human renal transplantation. Transplantation 1999;67:1036–42.PubMedCrossRefGoogle Scholar
  28. 28.
    Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000;69:1252–60.PubMedCrossRefGoogle Scholar
  29. 29.
    Hricik DE, O’Toole M, Schulak JA, et al. Steroid-free, cyclosporin-based immunosuppression after renal transplantation: a meta-analysis of controlled trials. J Am Soc Nephrol 1993;4:1300–5.PubMedGoogle Scholar
  30. 30.
    Ratcliffe PJ, Dudley CR, Higgins RM, et al. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996;348:643–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Vanrenterghem Y. Strategies to reduce or replace steroid dosing. Transplant Proc 1999;31(suppl):7–10.CrossRefGoogle Scholar
  32. 32.
    Swinnen LJ, Constanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990;323:1723–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Woodle ES, Thistlethwaite R, Gordon JH, et al. A multicentre trial of FK506 therapy in refractory acute renal allograft rejection. Transplantation 1996;62:594–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Mycophenolate Mofetil Acute Renal Rejection Study Group. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection. Transplantation 1998;65:235–41.Google Scholar
  35. 35.
    Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute cellular renal transplant rejection. Transplantation 1996;61:722–9.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2002

Authors and Affiliations

  • John J. Fung
  • J. Andrew Bradley

There are no affiliations available

Personalised recommendations